Cargando…
The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-3...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955714/ https://www.ncbi.nlm.nih.gov/pubmed/35324695 http://dx.doi.org/10.3390/toxins14030197 |
_version_ | 1784676403908706304 |
---|---|
author | Świerczyńska, Karolina Krajewski, Piotr K. Nowicka-Suszko, Danuta Białynicki-Birula, Rafał Krajewska, Magdalena Szepietowski, Jacek C. |
author_facet | Świerczyńska, Karolina Krajewski, Piotr K. Nowicka-Suszko, Danuta Białynicki-Birula, Rafał Krajewska, Magdalena Szepietowski, Jacek C. |
author_sort | Świerczyńska, Karolina |
collection | PubMed |
description | Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-31 (IL-31) to the pathogenesis of itch in patients undergoing maintenance hemodialysis (HD). We evaluated the serum level of IL-31 in HD patients with pruritus, in HD patients without pruritus and in healthy controls, as well as its correlation to the severity of itch. The study enrolled 175 adult subjects. The participants were divided into three groups. Group A included 64 patients on maintenance HD with CKD-aP, Group B included 62 patients on maintenance HD not reporting CKD-aP and Group C included 49 healthy controls. Pruritus severity was assessed using the Numerical Rating Scale (NRS), and the serum levels of IL-31 were measured. The results showed that the IL-31 serum level was significantly higher in the itchy group (p < 0.001) in comparison to the patients free from pruritus. Moreover, a marginal trend towards significance (r = 0.242, p = 0.058) was observed between the IL-31 serum level and itch intensity. Our study supports earlier findings on the extended role of IL-31 in the development of CKD-aP. |
format | Online Article Text |
id | pubmed-8955714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89557142022-03-26 The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? Świerczyńska, Karolina Krajewski, Piotr K. Nowicka-Suszko, Danuta Białynicki-Birula, Rafał Krajewska, Magdalena Szepietowski, Jacek C. Toxins (Basel) Article Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-31 (IL-31) to the pathogenesis of itch in patients undergoing maintenance hemodialysis (HD). We evaluated the serum level of IL-31 in HD patients with pruritus, in HD patients without pruritus and in healthy controls, as well as its correlation to the severity of itch. The study enrolled 175 adult subjects. The participants were divided into three groups. Group A included 64 patients on maintenance HD with CKD-aP, Group B included 62 patients on maintenance HD not reporting CKD-aP and Group C included 49 healthy controls. Pruritus severity was assessed using the Numerical Rating Scale (NRS), and the serum levels of IL-31 were measured. The results showed that the IL-31 serum level was significantly higher in the itchy group (p < 0.001) in comparison to the patients free from pruritus. Moreover, a marginal trend towards significance (r = 0.242, p = 0.058) was observed between the IL-31 serum level and itch intensity. Our study supports earlier findings on the extended role of IL-31 in the development of CKD-aP. MDPI 2022-03-07 /pmc/articles/PMC8955714/ /pubmed/35324695 http://dx.doi.org/10.3390/toxins14030197 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Świerczyńska, Karolina Krajewski, Piotr K. Nowicka-Suszko, Danuta Białynicki-Birula, Rafał Krajewska, Magdalena Szepietowski, Jacek C. The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? |
title | The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? |
title_full | The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? |
title_fullStr | The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? |
title_full_unstemmed | The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? |
title_short | The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect? |
title_sort | serum level of il-31 in patients with chronic kidney disease-associated pruritus: what can we expect? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955714/ https://www.ncbi.nlm.nih.gov/pubmed/35324695 http://dx.doi.org/10.3390/toxins14030197 |
work_keys_str_mv | AT swierczynskakarolina theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT krajewskipiotrk theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT nowickasuszkodanuta theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT białynickibirularafał theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT krajewskamagdalena theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT szepietowskijacekc theserumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT swierczynskakarolina serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT krajewskipiotrk serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT nowickasuszkodanuta serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT białynickibirularafał serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT krajewskamagdalena serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect AT szepietowskijacekc serumlevelofil31inpatientswithchronickidneydiseaseassociatedprurituswhatcanweexpect |